Page last updated: 2024-11-12
amooranin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
amooranin: isolated from Amoora rohituka; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Amoora | genus | [no description available] | Meliaceae | The mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11503749 |
SCHEMBL ID | 4150780 |
MeSH ID | M0423105 |
Synonyms (3)
Synonym |
---|
SCHEMBL4150780 |
amooranin |
(4as,6as,6as,6br,8ar,12as,14bs)-12a-(hydroxymethyl)-2,2,6a,6b,9,9-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid |
Research Excerpts
Overview
Amooranin is a triterpene acid isolated from the stem bark of a tropical tree (Amoora rohituka) grown wild in India.
Excerpt | Reference | Relevance |
---|---|---|
"Amooranin (AMR) is a triterpene acid isolated from the stem bark of a tropical tree (Amoora rohituka) grown wild in India. " | ( Novel drug amooranin induces apoptosis through caspase activity in human breast carcinoma cell lines. Alamo, A; Escalon, E; Fonseca, HB; Melnick, SJ; Nair, RP; Rabi, T; Ramachandran, C, 2003) | 2.15 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |